5 recruiting, 2 unknown, 1 active not recruiting, 1 completed. 7 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Unknown 2, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow daromun: new trials by email Literature Review of daromun trials Research Report on daromun
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) L19IL2, L19TNF, L19IL2/L19TNF - Locally Advanced Basal Cell Carcinoma | Phase 2 | Recruiting | Philogen S.p.A. | 180 | 2026-09-28 | 2026-11-10 |
| L19IL2/TNF in Patients With Basal Cell Carcinoma L19IL2/L19TNF - Locally Advanced Basal Cell Carcinoma | Phase 2 | Recruiting | Philogen S.p.A. | 92 | 2026-09-01 | 2026-07-21 |
| L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma L19IL2/L19TNF - Locally Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | Philogen S.p.A. | 92 | 2026-09-01 | 2026-07-24 |
| Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients L19IL2, L19TNF, L19IL2/L19TNF - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | Philogen S.p.A. | 162 | 2024-07-12 | 2026-09-02 |
| L19IL2/L19TNF in Skin Cancer Patients L19IL2/L19TNF - BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 2 | Unknown | Philogen S.p.A. | 70 | 2023-03-09 | 2023-10-06 |
| Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients L19IL2 +L19TNF - Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell | Phase 2 | Unknown | Philogen S.p.A. | 40 | 2020-09-02 | 2023-10-10 |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients Daromun, Surgery, Adjuvant therapy - Melanoma Stage IIIB, Melanoma Stage IIIC | Phase 3 | Recruiting | Philogen S.p.A. | 186 | 2018-09-20 | 2025-12-17 |
| Neoadjuvant L19IL2/L19TNF- Pivotal Study L19IL2 + L19TNF, Surgery - Malignant Melanoma | Phase 3 | Active not recruiting | Philogen S.p.A. | 214 | 2016-07-01 | 2024-09-19 |
| Intratumoral Administration of L19IL2/L19TNF L19IL2+L19TNF - Malignant Melanoma, Skin | Phase 2 | Completed | Philogen S.p.A. | 21 | 2012-12-01 | 2015-05-27 |
Carcinoma, Basal Cell (4) · Melanoma (4) · Carcinoma (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1) · Sarcoma, Kaposi (1)
Philogen S.p.A. (9)
Italy (7) · Germany (6) · Spain (5) · United States (5) · Greece (3) · France (2) · Poland (2) · Switzerland (2)
Caroline Robert, MD (1) · Danielle Bello (1) · Mario Santinami, Dr (1) · Mario Santinami, MD (1) · Piotr Rutkowski, MD (1)
PMID 36648215, PMID 31538818, PMID 40633690, PMID 42579833
2025 (3), 2023 (1)